echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Weight: Coren's first inhaler is here! The 20 billion market is heating up rapidly

    Weight: Coren's first inhaler is here! The 20 billion market is heating up rapidly

    • Last Update: 2021-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 28th, Colum's declaration of a class 4 imitation of the inhaled isopropyl tobly bromide solution was approved by CDE, the company's first inhaler, which attracted market attention.
    meters intranet data show that in China's public medical institutions terminal, the market size of inhalers in 2018 has exceeded 20 billion yuan, 2018-2019 growth rate of more than 10%, the first half of 2020 affected by the epidemic growth rate declined.
    Figure 1: Registration of isopropyl bromide solution for inhalation at Hunan Colum Pharmaceuticals Source: CDE Official Website Figure 2: Sales of isopropyl toblybhamide solution for inhalation Source: Isopropyl bromide for anti-ammonium for terminal competition in public medical institutions in China Choline-energy drugs, with strong bronchial smooth muscle relaxation, can significantly improve lung function and exercise tolerance in patients with chronic obstructive pulmonary disease (COPD), relieve the symptoms of respiratory difficulties, improve sleep and quality of life, is one of the main drugs to treat COPD.
    research products developed by Grigg Ingham, entered the domestic market in 2004, is the national health insurance catalog Class A varieties.
    meters intranet data show that in the first half of 2020 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal inhaler TOP20 products, inhalation of isopropyl tobly bromide solution ranked ninth, the product has grown to more than 1 billion products from 2018.
    table 1: Isopropyl tobly bromide inhalants currently under review are involved in the enterprise situation source: MED2.0 China Drug Review Database, the product by the original pharmaceutical companies leading the market, the market share in the first half of 2020 is still more than 90%.
    In 2020, the four generics of Shenzhen Mrs. Pharmaceuticals and Four Trump Rite Pharmaceuticals were approved and evaluated as such, and there are currently seven applications for the listing of isopropyl toblyblycide-related inhalants.
    By virtue of Colum's strength, after successful approval is expected to become a strong competitor to the original research products, the beginning of 2021 is not more than a month, Colum has seven high-end generic drugs declared on the market and in the review and approval, the next two to three years will also be the big infusion leader new products approved blowout period.
    form 2: 2021 to date Colum declared the listing and review of the product situation Source: MED2.0 China Drug Review Database Source: CDE official website, Minet database review data statistics as of January 28, 2021, if there are errors, please refer to the right.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.